Filing Details
- Accession Number:
- 0001209191-24-000367
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-03 16:20:30
- Reporting Period:
- 2023-12-31
- Accepted Time:
- 2024-01-03 16:20:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1787297 | Passage Bio Inc. | PASG | Biological Products, (No Disgnostic Substances) (2836) | 822729751 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1987062 | Kathleen Borthwick | One Commerce Square 2005 Market Street, 39Th Floor Philadelphia PA 19103 | Svp, Interim Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-12-31 | 30,000 | $0.00 | 36,608 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-01-02 | 10,672 | $0.91 | 25,936 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Unit | Disposition | 2023-12-31 | 30,000 | $0.00 | 30,000 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | M | Direct |
Footnotes
- Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- Includes 3,082 shares acquired on May 13, 2022 and 3,526 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan.
- The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
- Each RSU represents a contingent right to receive one share of Issuer's common stock.
- 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.